Show simple item record

AuthorDanjuma, Mohammed Ibn-Mas'ud
AuthorMohamed, Mouhand F H
AuthorElShafei, Mohamad Nabil
AuthorFatima, Haajra
AuthorShokri, Shaikha Al
AuthorMohamed, Sara
AuthorAbubeker, Ibrahim Yusuf
AuthorKartha, Anand
AuthorElzouki, Abdel-Naser
AuthorMohamedali, Mohamed Gaafar Hussein
AuthorMahgboub, Yahya
AuthorBidmos, Mubarak
Available date2020-05-31T05:01:27Z
Publication Date2020-04-01
Publication NameMedicine
Identifierhttp://dx.doi.org/10.1097/MD.0000000000019679
CitationAPA Danjuma, Mohammed ibn-Mas’ud MBBS, MSca,b,∗; Mohamed, Mouhand F.H. MDb; ElShafei, Mohamad Nabil Pharm Db; Fatima, Haajra MBBSb; Shokri, Shaikha Al MDb; Mohamed, Sara MBBSb; Abubeker, Ibrahim Yusuf MD, CABHSc; Kartha, Anand MD, MS, SFHMb; Elzouki, Abdel-Naser MD, PhDa,b; Mohamedali, Mohamed Gaafar Hussein MDb; Mahgboub, Yahya MBBS, MScd; Bidmos, Mubarak MBBS, MSc, PhDa Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients, Medicine: April 2020 - Volume 99 - Issue 14 - p e19679 doi: 10.1097/MD.0000000000019679
ISSN0025-7974
URIhttp://hdl.handle.net/10576/14977
AbstractThere has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients. We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool. We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT. Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.
Languageen
PublisherLippincott, Williams & Wilkins
Subjectcancer associated thrombosis
cancer thrombosis
DOAC
DVT
NOAC
novel oral anticoagulant
pulmonary embolism
TitleComparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology.
TypeArticle
Paginatione19679
Issue Number14
Volume Number99
ESSN1536-5964


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record